Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor
Status:
Completed
Trial end date:
2016-03-03
Target enrollment:
Participant gender:
Summary
This is a multicenter study evaluating the safety and tolerability of Toca 511 administered
intravenously to patients with recurrent or progressive Grade III or Grade IV Gliomas who
have elected to undergo surgical removal of their tumor. Patients meeting all of the
inclusion and none of the exclusion criteria will receive an initial dose of Toca 511
administered as an intravenous, bolus injection, followed approximately 11 days later by an
additional dose injected into the walls of the resection cavity at the time of planned tumor
resection. Approximately 6 weeks later, patients will begin treatment with oral Toca FC, an
antifungal agent, and repeated every 4 weeks. All patients enrolled in this study will be
encouraged to participate in a continuation protocol that enables additional Toca FC
administration and the collection of long-term safety and response data.